266 related articles for article (PubMed ID: 29269513)
21. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of novel and potent protease activated receptor 4 (PAR4) antagonists based on a quinazolin-4(3H)-one scaffold.
Liu S; Yuan D; Li S; Xie R; Kong Y; Zhu X
Eur J Med Chem; 2021 Dec; 225():113764. PubMed ID: 34391031
[TBL] [Abstract][Full Text] [Related]
23. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
Vilahur G; Segalés E; Salas E; Badimon L
Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
[TBL] [Abstract][Full Text] [Related]
24. Oligosaccharide Blocks PAR1 (Proteinase-Activated Receptor 1)-PAR4-Mediated Platelet Activation by Binding to Thrombin Exosite II and Impairs Thrombosis.
Li S; Wang W; Lin L; Yang L; Cai Y; Yang X; Zhang T; Xiao C; Yan H; Gao N; Zhao J
Arterioscler Thromb Vasc Biol; 2023 Feb; 43(2):253-266. PubMed ID: 36519467
[TBL] [Abstract][Full Text] [Related]
25. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study.
Zafar MU; Ibáñez B; Choi BG; Vorchheimer DA; Piñero A; Jin X; Sharma RK; Badimon JJ
Thromb Haemost; 2010 Jan; 103(1):205-12. PubMed ID: 20062928
[TBL] [Abstract][Full Text] [Related]
26. Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans.
Japp AG; Chelliah R; Tattersall L; Lang NN; Meng X; Weisel K; Katz A; Burt D; Fox KA; Feuerstein GZ; Connolly TM; Newby DE
J Am Heart Assoc; 2013 Jan; 2(1):e006007. PubMed ID: 23525448
[TBL] [Abstract][Full Text] [Related]
27. Effects of P2Y(1) receptor antagonism on the reactivity of platelets from patients with stable coronary artery disease using aspirin and clopidogrel.
Labarthe B; Babin J; Bryckaert M; Théroux P; Bonnefoy A
Br J Pharmacol; 2012 May; 166(1):221-31. PubMed ID: 21950486
[TBL] [Abstract][Full Text] [Related]
28. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
29. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
30. The roles and mechanisms of PAR4 and P2Y12/phosphatidylinositol 3-kinase pathway in maintaining thrombin-induced platelet aggregation.
Wu CC; Wu SY; Liao CY; Teng CM; Wu YC; Kuo SC
Br J Pharmacol; 2010 Oct; 161(3):643-58. PubMed ID: 20880402
[TBL] [Abstract][Full Text] [Related]
31. Effect of Different Doses of Acetylsalicylic Acid on the Antithrombotic Activity of Clopidogrel in a Mouse Arterial Thrombosis Model.
Ni R; Vaezzadeh N; Zhou J; Weitz JI; Cattaneo M; Gross PL
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2338-2344. PubMed ID: 30354213
[TBL] [Abstract][Full Text] [Related]
32. Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis.
Van Doren L; Nguyen N; Garzia C; Fletcher EK; Stevenson R; Jaramillo D; Kuliopulos A; Covic L
Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):e33-e45. PubMed ID: 33267659
[TBL] [Abstract][Full Text] [Related]
33. Comparison of PD0348292, a selective factor Xa inhibitor, to antiplatelet agents for the inhibition of arterial thrombosis.
Karnicki K; Leadley RJ; Baxi S; Peterson T; Wysokinski W; McBane RD
Thromb Haemost; 2008 Apr; 99(4):759-66. PubMed ID: 18392334
[TBL] [Abstract][Full Text] [Related]
34. Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.
Miller MM; Banville J; Friends TJ; Gagnon M; Hangeland JJ; Lavallée JF; Martel A; O'Grady H; Rémillard R; Ruediger E; Tremblay F; Posy SL; Allegretto NJ; Guarino VR; Harden DG; Harper TW; Hartl K; Josephs J; Malmstrom S; Watson C; Yang Y; Zhang G; Wong P; Yang J; Bouvier M; Seiffert DA; Wexler RR; Lawrence RM; Priestley ES; Marinier A
J Med Chem; 2019 Aug; 62(16):7400-7416. PubMed ID: 31246024
[TBL] [Abstract][Full Text] [Related]
35. Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents.
Liu S; Li S; Yuan D; Wang E; Xie R; Zhang W; Kong Y; Zhu X
Eur J Med Chem; 2021 Jan; 209():112893. PubMed ID: 33049608
[TBL] [Abstract][Full Text] [Related]
36. Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.
Nylander S; Kull B; Björkman JA; Ulvinge JC; Oakes N; Emanuelsson BM; Andersson M; Skärby T; Inghardt T; Fjellström O; Gustafsson D
J Thromb Haemost; 2012 Oct; 10(10):2127-36. PubMed ID: 22906130
[TBL] [Abstract][Full Text] [Related]
37. Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic study.
Rollini F; Franchi F; Cho JR; Degroat C; Bhatti M; Ferrante E; Patel R; Darlington A; Tello-Montoliu A; Desai B; Ferreiro J; Muniz-Lozano A; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
J Cardiovasc Transl Res; 2014 Feb; 7(1):53-63. PubMed ID: 24395495
[TBL] [Abstract][Full Text] [Related]
38. Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.
Gurbel PA; Bliden KP; Turner SE; Tantry US; Gesheff MG; Barr TP; Covic L; Kuliopulos A
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):189-97. PubMed ID: 26681756
[TBL] [Abstract][Full Text] [Related]
39. Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Prasugrel-Inhibited Platelets: Results of a Prospective, Randomized, Crossover Study (the ECCLIPSE Trial).
Vivas D; Martín A; Bernardo E; Ortega-Pozzi MA; Tirado G; Fernández C; Vilacosta I; Núñez-Gil I; Macaya C; Fernández-Ortiz A
Circ Cardiovasc Interv; 2015 May; 8(5):. PubMed ID: 25957056
[TBL] [Abstract][Full Text] [Related]
40. Safety and Pharmacokinetics of DS-1040 Drug-Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin.
Limsakun T; Dishy V; Mendell J; Pizzagalli F; Pav J; Kochan J; Vandell AG; Rambaran C; Kobayashi F; Orihashi Y; Warren V; McPhillips P; Zhou J
J Clin Pharmacol; 2020 Jun; 60(6):691-701. PubMed ID: 32106339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
